SPRO
Spero Therapeutics, Inc.
Biotechnology
Market Cap$141M
5Y Perf.-78.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SPRO vs VNDA
Revenue, margins, valuation, and 5-year total return — side by side.
VNDA
Vanda Pharmaceuticals Inc.
Biotechnology
Market Cap$378M
5Y Perf.-45.5%
SPRO vs VNDA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SPRO | VNDA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $141M | $378M |
| Revenue (TTM) | $36M | $218M |
| Net Income (TTM) | $-44M | $-240M |
| Gross Margin | -202.6% | 71.1% |
| Operating Margin | -130.9% | -73.6% |
| Forward P/E | 3.7x | — |
| Total Debt | $4M | $13M |
| Cash & Equiv. | $53M | $85M |
SPRO vs VNDA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SPRO
VNDA
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Spero Therapeutics,… (SPRO) | 100 | 21.2 | -78.8% |
| Vanda Pharmaceutica… (VNDA) | 100 | 54.5 | -45.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SPRO vs VNDA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: VNDA leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Spero Therapeutics, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
SPRO
Spero Therapeutics, Inc.
The Income Pick
SPRO is the clearest fit if your priority is income & stability and growth exposure.
- beta 0.90
- Rev growth -53.8%, EPS growth -395.3%, 3Y rev CAGR 150.0%
- Lower volatility, beta 0.90, Low D/E 9.3%, current ratio 2.19x
Best for: income & stability and growth exposure
VNDA
Vanda Pharmaceuticals Inc.
The Long-Run Compounder
VNDA carries the broadest edge in this set and is the clearest fit for long-term compounding.
- -26.8% 10Y total return vs SPRO's -78.2%
- 8.7% revenue growth vs SPRO's -53.8%
- -110.0% margin vs SPRO's -122.6%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | VNDA | 8.7% revenue growth vs SPRO's -53.8% |
| Quality / Margins | VNDA | -110.0% margin vs SPRO's -122.6% |
| Stability / Safety | SPRO | Beta 0.90 vs VNDA's 1.04 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | SPRO | +334.3% vs VNDA's +45.9% |
| Efficiency (ROA) | VNDA | -44.6% ROA vs SPRO's -80.9%, ROIC -32.2% vs -327.2% |
SPRO vs VNDA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2025
SPRO vs VNDA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLVNDALAGGINGSPRO
SPROSpero Therapeutics, I…
2leads
VNDAVanda Pharmaceuticals…
3leads
6 Total Categories
CATEGORYLEADERvs SPROMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
VNDA5/6
Valuation MetricsMultiples, price ratios, and targets
VNDA2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
VNDA7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
SPRO4/6
Risk & VolatilityBeta, volatility, and downside exposure
SPRO2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
VNDA leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
VNDA is the larger business by revenue, generating $218M annually — 6.1x SPRO's $36M. VNDA is the more profitable business, keeping -110.0% of every revenue dollar as net income compared to SPRO's -122.6%. On growth, VNDA holds the edge at +3.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SPROSpero Therapeutic… | VNDAVanda Pharmaceuti… |
|---|---|---|
| RevenueTrailing 12 months | $36M | $218M |
| EBITDAEarnings before interest/tax | -$45M | -$150M |
| Net IncomeAfter-tax profit | -$44M | -$240M |
| Free Cash FlowCash after capex | -$28M | -$127M |
| Gross MarginGross profit ÷ Revenue | -2.0% | +71.1% |
| Operating MarginEBIT ÷ Revenue | -130.9% | -73.6% |
| Net MarginNet income ÷ Revenue | -122.6% | -110.0% |
| FCF MarginFCF ÷ Revenue | -77.4% | -58.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -77.4% | +3.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +59.4% | -64.0% |
VNDA leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
VNDA leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | SPROSpero Therapeutic… | VNDAVanda Pharmaceuti… |
|---|---|---|
| Market CapShares × price | $141M | $378M |
| Enterprise ValueMkt cap + debt − cash | $93M | $305M |
| Trailing P/EPrice ÷ TTM EPS | -1.98x | -1.71x |
| Forward P/EPrice ÷ next-FY EPS est. | 3.75x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 2.95x | 1.75x |
| Price / BookPrice ÷ Book value/share | 2.94x | 1.15x |
| Price / FCFMarket cap ÷ FCF | — | — |
VNDA leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
VNDA leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
VNDA delivers a -61.4% return on equity — every $100 of shareholder capital generates $-61 in annual profit, vs $-165 for SPRO. VNDA carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to SPRO's 0.09x. On the Piotroski fundamental quality scale (0–9), VNDA scores 2/9 vs SPRO's 1/9, reflecting mixed financial health.
| Metric | SPROSpero Therapeutic… | VNDAVanda Pharmaceuti… |
|---|---|---|
| ROE (TTM)Return on equity | -165.5% | -61.4% |
| ROA (TTM)Return on assets | -80.9% | -44.6% |
| ROICReturn on invested capital | -3.3% | -32.2% |
| ROCEReturn on capital employed | -71.0% | -33.6% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 2 |
| Debt / EquityFinancial leverage | 0.09x | 0.04x |
| Net DebtTotal debt minus cash | -$49M | -$72M |
| Cash & Equiv.Liquid assets | $53M | $85M |
| Total DebtShort + long-term debt | $4M | $13M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
VNDA leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
SPRO leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in VNDA five years ago would be worth $3,578 today (with dividends reinvested), compared to $1,870 for SPRO. Over the past 12 months, SPRO leads with a +334.3% total return vs VNDA's +45.9%. The 3-year compound annual growth rate (CAGR) favors SPRO at 9.7% vs VNDA's -2.7% — a key indicator of consistent wealth creation.
| Metric | SPROSpero Therapeutic… | VNDAVanda Pharmaceuti… |
|---|---|---|
| YTD ReturnYear-to-date | +6.8% | -22.5% |
| 1-Year ReturnPast 12 months | +334.3% | +45.9% |
| 3-Year ReturnCumulative with dividends | +32.1% | -7.8% |
| 5-Year ReturnCumulative with dividends | -81.3% | -64.2% |
| 10-Year ReturnCumulative with dividends | -78.2% | -26.8% |
| CAGR (3Y)Annualised 3-year return | +9.7% | -2.7% |
SPRO leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
SPRO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
SPRO is the less volatile stock with a 0.90 beta — it tends to amplify market swings less than VNDA's 1.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SPRO currently trades 78.0% from its 52-week high vs VNDA's 64.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SPROSpero Therapeutic… | VNDAVanda Pharmaceuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.90x | 1.04x |
| 52-Week HighHighest price in past year | $3.22 | $9.94 |
| 52-Week LowLowest price in past year | $0.57 | $3.81 |
| % of 52W HighCurrent price vs 52-week peak | +78.0% | +64.3% |
| RSI (14)Momentum oscillator 0–100 | 46.6 | 54.9 |
| Avg Volume (50D)Average daily shares traded | 384K | 1.6M |
SPRO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates SPRO as "Buy" and VNDA as "Buy".
| Metric | SPROSpero Therapeutic… | VNDAVanda Pharmaceuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $14.17 |
| # AnalystsCovering analysts | 13 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
VNDA leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). SPRO leads in 2 (Total Returns, Risk & Volatility).
Best OverallVanda Pharmaceuticals Inc. (VNDA)Leads 3 of 6 categories
Loading custom metrics...
SPRO vs VNDA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SPRO or VNDA a better buy right now?
For growth investors, Vanda Pharmaceuticals Inc.
(VNDA) is the stronger pick with 8. 7% revenue growth year-over-year, versus -53. 8% for Spero Therapeutics, Inc. (SPRO). Analysts rate Spero Therapeutics, Inc. (SPRO) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SPRO or VNDA?
Over the past 5 years, Vanda Pharmaceuticals Inc.
(VNDA) delivered a total return of -64. 2%, compared to -81. 3% for Spero Therapeutics, Inc. (SPRO). Over 10 years, the gap is even starker: VNDA returned -26. 8% versus SPRO's -78. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SPRO or VNDA?
By beta (market sensitivity over 5 years), Spero Therapeutics, Inc.
(SPRO) is the lower-risk stock at 0. 90β versus Vanda Pharmaceuticals Inc. 's 1. 04β — meaning VNDA is approximately 15% more volatile than SPRO relative to the S&P 500. On balance sheet safety, Vanda Pharmaceuticals Inc. (VNDA) carries a lower debt/equity ratio of 4% versus 9% for Spero Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — SPRO or VNDA?
By revenue growth (latest reported year), Vanda Pharmaceuticals Inc.
(VNDA) is pulling ahead at 8. 7% versus -53. 8% for Spero Therapeutics, Inc. (SPRO). On earnings-per-share growth, the picture is similar: Spero Therapeutics, Inc. grew EPS -395. 3% year-over-year, compared to -1068. 8% for Vanda Pharmaceuticals Inc.. Over a 3-year CAGR, SPRO leads at 150. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SPRO or VNDA?
Vanda Pharmaceuticals Inc.
(VNDA) is the more profitable company, earning -102. 0% net margin versus -142. 9% for Spero Therapeutics, Inc. — meaning it keeps -102. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VNDA leads at -70. 0% versus -152. 9% for SPRO. At the gross margin level — before operating expenses — VNDA leads at 94. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SPRO or VNDA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SPRO or VNDA better for a retirement portfolio?
For long-horizon retirement investors, Spero Therapeutics, Inc.
(SPRO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90)). Both have compounded well over 10 years (SPRO: -78. 2%, VNDA: -26. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SPRO and VNDA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(SPRO: -77.4% · VNDA: 3.4%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.